Curcumin has been studied as a potential anticancer drug for many years, not only because of its antiproliferative or apoptosis-inducing effect on several cancer cells, but also due to its ability to reverse MDR phenotypes in several cancer cells overexpressing ABC transporters, such as, ABCB1, ABCC1, and ABCG2 (Sharma et al., 2009). This evidence concerns the gene ABCB1 and cancer.